Reduced-Dose Hypofractionated Radiation Therapy (3 Gy × 3 Fractions) for Indolent Non-Hodgkin's lymphoma (POSEIDON): A Multisite Phase 2 Randomized Trial Protocol.

ABSTRACT: Indolent non-Hodgkin's lymphoma, including follicular and marginal zone lymphoma, is highly radiosensitive, with radiation therapy (RT) serving as an effective treatment. Although standard RT doses (24 Gy in 12 fractions) provide excellent disease control, they are associated with toxicity. Emerging evidence suggests that lower RT doses may maintain efficacy while reducing toxicity; however, prior prospective randomized attempts to reduce the dose to 4 Gy in 2 fractions have demonstrated inferior disease control. This phase 2 randomized trial aims to determine whether reduced-dose hypofractionated RT can achieve comparable disease control while minimizing toxicity and treatment burden. Patients will be randomized 1:1 to receive experimental arm treatment with 8 to 10 Gy in 2 to 5 fractions

SUBMITTER: Saifi O 

PROVIDER: S-EPMC12686686 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature